Rate My Professor Feng Li

Professor Li's research interests include LC-MS-based metabolomics, drug metabolism and pharmacokinetics, drug-induced liver injury, blood-testis barrier, and imaging mass spectrometry. His work examines cytochrome P450-mediated drug metabolism, hepatotoxicity mechanisms, and tissue-specific distribution of drugs and metabolites. Supported by NIH grants such as R01DK121970 (NIH/NIDDK) on mechanisms of liver toxicity of anti-depressant duloxetine and R33HD099995 (NIH/NICHD) on chemical features affecting passage across the blood-testis and blood-epididymal barriers in mice. Key publications are "Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy" (Nature Medicine, 2013), "CYP3A Mediates an Unusual C(sp²)-C(sp³) Bond Cleavage via Ipso-Addition of Oxygen in Drug Metabolism" (Angewandte Chemie International Edition, 2024), "MALDI Imaging Mass Spectrometry Visualizes the Distribution of Antidepressant Duloxetine and Its Major Metabolites in Mouse Brain, Liver, Kidney, and Spleen Tissues" (Drug Metabolism & Disposition, 2024), "Metabolism, Pharmacokinetics, and Tissue Distribution of a Selective FK506-Binding Protein 12 F36V Mutant Degrader in Mice" (ACS Pharmacology & Translational Science, 2025), and "The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice" (European Journal of Pharmaceutical Sciences, 2023).